Ghana Set to Exit GAVI Vaccine Support by 2030 – President Mahama Says
President John Dramani Mahama has announced that Ghana is on course to transition out of funding support from GAVI, the global vaccine alliance, by 2030, marking a major milestone in the country’s healthcare financing and immunisation development agenda.
Addressing delegates at the 79th World Health Assembly in Geneva, Switzerland, President Mahama said Ghana’s improving healthcare systems and expanding vaccine financing capacity have positioned the country to move gradually from being a recipient of donor-backed vaccine support to potentially becoming a contributor to global immunisation efforts.
“Ghana is on track to exit GAVI funding for vaccines by the year 2030, and we hope to transition into a donor in the not-too-distant future,” the President stated.
The announcement signals a significant shift in Ghana’s health financing trajectory. For years, GAVI has supported Ghana’s immunisation programmes through funding, technical assistance and partnerships covering vaccines for diseases such as measles, polio, pneumococcal infections, yellow fever, rotavirus and human papillomavirus.
Under GAVI’s graduation framework, countries that achieve sustained economic growth and improved income levels are gradually transitioned away from donor dependence and expected to finance their national vaccine programmes independently.
For Ghana, the planned 2030 exit would reflect progress in strengthening national health infrastructure, expanding vaccine coverage and improving access to essential immunisation services across the country.
Vaccine graduation means Ghana will have to assume greater responsibility for procurement, cold-chain systems, logistics, nationwide distribution and programme sustainability. That transition will require predictable budgetary allocations, stronger public financial management and long-term planning to ensure that immunisation gains are not reversed.
President Mahama’s comments come at a time when African governments are under increasing pressure to strengthen domestic healthcare financing amid declining global aid flows and growing uncertainty around international development assistance.
Recent concerns over shrinking donor support have sharpened that debate. Ghana reportedly lost about US$78 million in health funding linked to the closure of USAID-backed programmes, underscoring the vulnerability of public health systems that remain heavily exposed to external financing.
The President also used his address to highlight government’s broader healthcare reform agenda under the MahamaCares initiative, which seeks to improve access to specialised and high-cost medical treatment for vulnerable populations. The initiative is expected to form part of government’s wider attempt to strengthen health access, reduce the burden of catastrophic medical expenses and deepen the country’s capacity to provide treatment for conditions that often push households into financial distress.
Health policy analysts say Ghana’s planned transition from GAVI support signals growing institutional maturity within the health sector. However, they caution that the shift must be matched with stronger domestic revenue mobilisation and dedicated health financing reforms.
The risk is that vaccine independence could become a burden if fiscal space remains tight.
Ghana is emerging from a period of debt restructuring and IMF-backed reforms, with government under pressure to sustain fiscal consolidation, reduce borrowing and manage competing demands across education, infrastructure, energy and social protection.
In that context, independent vaccine financing will require political discipline. Immunisation budgets must be protected even during periods of fiscal stress, because delayed procurement or weak coverage can quickly expose children and vulnerable populations to preventable diseases. The broader significance of the President’s announcement is that Ghana is seeking to move from aid dependence toward health sovereignty.
That ambition fits into a wider African conversation on self-reliance in healthcare financing, local vaccine production, medical supply chains and pandemic preparedness. The COVID-19 pandemic exposed how vulnerable African countries can be when essential vaccines and medical products are dependent on global supply chains controlled elsewhere.
For Ghana, exiting GAVI support by 2030 would be a vote of confidence in the country’s health systems. But the transition must be managed carefully.
The country will need to ensure that vaccine affordability, procurement efficiency, storage capacity, rural delivery and public trust in immunisation remain strong after donor financing reduces.
The policy question is not whether Ghana should graduate from GAVI support. Graduation is a sign of progress. The deeper question is whether the country can finance immunisation sustainably without allowing coverage gaps to emerge.
President Mahama’s message in Geneva was therefore both aspirational and demanding.
Ghana may be preparing to leave behind donor-backed vaccine dependence, but the next phase will require stronger institutions, reliable budgets and a healthcare financing model capable of protecting every child, every district and every immunisation programme without waiting for external support.
If successfully managed, the 2030 transition could mark a defining moment in Ghana’s public health journey from vaccine aid recipient to self-financing health system and, eventually, as the President suggested, a contributor to global immunisation solidarity.
